These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1082 related articles for article (PubMed ID: 24418728)

  • 1. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
    Lira ME; Kim TM; Huang D; Deng S; Koh Y; Jang B; Go H; Lee SH; Chung DH; Kim WH; Schoenmakers EF; Choi YL; Park K; Ahn JS; Sun JM; Ahn MJ; Kim DW; Mao M
    J Mol Diagn; 2013 Jan; 15(1):51-61. PubMed ID: 23246132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
    Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
    Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
    Wijesinghe P; Bepler G; Bollig-Fischer A
    J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
    Gainor JF; Shaw AT
    Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
    Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
    Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
    Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
    Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z; Yu X; Zhang Y
    Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
    Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
    Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.
    Rogers TM; Arnau GM; Ryland GL; Huang S; Lira ME; Emmanuel Y; Perez OD; Irwin D; Fellowes AP; Wong SQ; Fox SB
    Sci Rep; 2017 Feb; 7():42259. PubMed ID: 28181564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.
    Lindquist KE; Karlsson A; Levéen P; Brunnström H; Reuterswärd C; Holm K; Jönsson M; Annersten K; Rosengren F; Jirström K; Kosieradzki J; Ek L; Borg Å; Planck M; Jönsson G; Staaf J
    Oncotarget; 2017 May; 8(21):34796-34810. PubMed ID: 28415793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.